- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04365569
Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program
September 25, 2025 updated by: Case Comprehensive Cancer Center
Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program on Body Weight, Composition, Cardiovascular Function and Quality of Life in Breast Cancer Survivors
More than 65% of breast cancer survivors are overweight and less than one-third participate in recommended levels of physical exercise.
Obese breast cancer survivors have been found to have greater than a two-fold increase in mortality compared to women with normal body mass index (BMI).
The current standard for weight loss interventions involves in-person counseling.
However, this incurs costs related to travel for counseling sessions, potentially limiting program participation, compliance and sustainability.This is a pilot study of an individualized in-person and telephone-based nutrition and exercise counseling program.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
78
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Weston, Florida, United States, 33331
- Cleveland Clinic Florida Weston, Case Comprehensive Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Breast cancer diagnosis (stage 0-III)
- Body mass index of 25mg/k2 or greater
- Actively being followed by medical oncologist, radiation oncologist, and/or breast surgeon at Maroone Cancer Center
- Able and willing to participate in nutrition counseling at Maroone Cancer Center
- Able (cleared by participant's primary oncologist) and willing to perform cardiopulmonary exercise testing
- Participants must have the ability to understand and the willingness to sign a written informed consent document
- Performance status 0 or 1 as per ECOG scale [see Appendix IV]
Exclusion Criteria:
- Body mass index below 25kg/m2
- No prior history of breast cancer
- History of metastatic disease
- Not being followed by medical oncologist, radiation oncologist, and/or breast surgeon at Maroone Cancer Center
- Unable or unwilling to participate in nutrition counseling at Maroone Cancer Center
- Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Participants actively undergoing chemotherapy, immunotherapy or radiation treatment. However, participants currently taking hormonal therapy, such as selective estrogen receptor modulators (SERMS), or aromatase inhibitors, may be included in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Individualized, nutrition and physical activity intervention
Initial in-person consult with a registered dietitian, with further in-person follow-ups and monthly telephone consults
|
6-month interventional, counseling program based on nutrition and physical activity consisting of: 1. Nutritional counseling by a Registered Dietitian (RD) 2) Implementation of an adequate physical activity program |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of participants achieving 10% weight loss
Time Frame: At baseline
|
Efficacy of intervention as assessed by percent of participants achieving 10% weight loss
|
At baseline
|
|
Percent of participants achieving 10% weight loss
Time Frame: At 3 months
|
Efficacy of intervention as assessed by percent of participants achieving 10% weight loss
|
At 3 months
|
|
Percent of participants achieving 10% weight loss
Time Frame: At 6 months
|
Efficacy of intervention as assessed by percent of participants achieving 10% weight loss
|
At 6 months
|
|
Compliance to the recommended dietary pattern
Time Frame: At 3 months
|
Assess compliance to the recommended dietary pattern, diet quality scores will be calculated by the RD after monthly telephone consults or in-person at 3 months and 6 months into the intervention.
Each of the 3 elements will be scored from 0-3, resulting in a total score range from 0-9
|
At 3 months
|
|
Compliance to physical activity goal
Time Frame: At 6 months
|
Percent of participants complying with proposed activity goal of 150 minutes of moderate intensity physical activity or 75 minutes of vigerous intensity physical activity (or a combination of both) per week over six months
|
At 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body fat percentage
Time Frame: Baseline
|
Body fat percentage measured by the registered dietitian (RD) using bioelectrical impedance analysis
|
Baseline
|
|
Body fat percentage
Time Frame: 3 months
|
Body fat percentage measured by the registered dietitian (RD) using bioelectrical impedance analysis
|
3 months
|
|
Body fat percentage
Time Frame: 6 months
|
Body fat percentage measured by the registered dietitian (RD) using bioelectrical impedance analysis
|
6 months
|
|
Glycemic control as measured by HbA1c
Time Frame: At 3 months
|
Glycemic control as measured by HbA1c
|
At 3 months
|
|
Glycemic control as measured by HbA1c
Time Frame: At 6 months
|
Glycemic control as measured by HbA1c
|
At 6 months
|
|
Cholesterol
Time Frame: At 3 months
|
Effect of the intervention on lipid profile as measured by high density cholesterol levels
|
At 3 months
|
|
Cholesterol
Time Frame: At 6 months
|
Effect of the intervention on lipid profile as measured by high density cholesterol levels
|
At 6 months
|
|
Low density lipoprotein
Time Frame: At 3 months
|
Effect of the intervention on lipid profile as measured by low density lipoprotein levels
|
At 3 months
|
|
Low density lipoprotein
Time Frame: At 6 months
|
Effect of the intervention on lipid profile as measured by low density lipoprotein levels
|
At 6 months
|
|
high density lipoprotein
Time Frame: At 3 months
|
Effect of the intervention on lipid profile as measured by high density lipoprotein levels
|
At 3 months
|
|
high density lipoprotein
Time Frame: At 6 months
|
Effect of the intervention on lipid profile as measured by high density lipoprotein levels
|
At 6 months
|
|
Triglycerides
Time Frame: At 3 months
|
Effect of the intervention on lipid profile as measured by triglyceride levels
|
At 3 months
|
|
Triglycerides
Time Frame: At 6 months
|
Effect of the intervention on lipid profile as measured by triglyceride levels
|
At 6 months
|
|
Serum vitamin D
Time Frame: At 3 months
|
Effect of the intervention on serum vitamin D
|
At 3 months
|
|
Serum vitamin D
Time Frame: At 6 months
|
Effect of the intervention on serum vitamin D
|
At 6 months
|
|
Serum C-reactive protein (CRP)
Time Frame: At 3 months
|
Effect of the intervention on CRP
|
At 3 months
|
|
Serum C-reactive protein (CRP)
Time Frame: At 6 months
|
Effect of the intervention on CRP
|
At 6 months
|
|
Maximum oxygen uptake as measured by VO2 max
Time Frame: Baseline
|
Maximum oxygen uptake as measured by VO2 max
|
Baseline
|
|
Maximum oxygen uptake as measured by VO2 max
Time Frame: At 3 months
|
Maximum oxygen uptake as measured by VO2 max
|
At 3 months
|
|
Maximum oxygen uptake as measured by VO2 max
Time Frame: At 6 months
|
Maximum oxygen uptake as measured by VO2 max
|
At 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life as measured by Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)
Time Frame: Baseline, 3 months and 6 months
|
Quality of life as measured by Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B), a 36-item self-report questionnaire to assess the quality of life as reported by breast cancer survivors with scores ranging from 0 to 123, and lower scores indicating better health.
|
Baseline, 3 months and 6 months
|
|
Quality of life as measured by Brief Pain Inventory (BPI)
Time Frame: Baseline, 3 months and 6 months
|
Quality of life as measured by Brief Pain Inventory (BPI), a 9-item self-administered questionnaire that can evaluate the effect of an individual's pain on their daily functioning.
This is a 10-point scale with 0 being the best possible score, meaning "no pain", and 10 being the worst possible score, meaning "pain as bad as you can imagine"
|
Baseline, 3 months and 6 months
|
|
Quality of life as measured by Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Baseline, 3 months and 6 months
|
Quality of life as measured by Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report questionnaire measuring anxiety which uses a four-point rating scale (ranging from 0 to 3) asking how often in the last two weeks participants have experienced symptoms pertaining to feeling anxious, worried, difficulty relaxing, and irritability.
Higher scores indicate higher distress.
with a possible score range of 0 to 21 with higher scores indicating worse anxiety.
|
Baseline, 3 months and 6 months
|
|
Quality of life as measured by Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline, 3 months and 6 months
|
Quality of life as measured by Patient Health Questionnaire-9 (PHQ-9), which objectifies degree of depression severity with a possible score range of 0 to 27 and higher scores indicating worse outcomes
|
Baseline, 3 months and 6 months
|
|
Quality of life as measured by NCCN Distress Thermometer
Time Frame: Baseline, 3 months and 6 months
|
Quality of life as measured by NCCN Distress Thermometer, which measures distress on a scale of 0 to 10, with higher scores indicating worse distress
|
Baseline, 3 months and 6 months
|
|
Factors associated with adherence to the program
Time Frame: At 6 months
|
Factors to be assessed include age, race, time since diagnosis, time since last chemotherapy, medical comorbidities and other lifestyle factors such as alcohol consumption and smoking
|
At 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Elizabeth Stone, MD, Cleveland Clinic, Case Comprehensive Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2021
Primary Completion (Actual)
May 16, 2024
Study Completion (Actual)
May 16, 2024
Study Registration Dates
First Submitted
April 23, 2020
First Submitted That Met QC Criteria
April 24, 2020
First Posted (Actual)
April 28, 2020
Study Record Updates
Last Update Posted (Estimated)
September 29, 2025
Last Update Submitted That Met QC Criteria
September 25, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE11119
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Will share IPD with other researchers within the same institution, but not outside the institution
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Nutrition and physical activity counseling program
-
KU LeuvenFund for Scientific Research, Flanders, BelgiumUnknownChronic Obstructive Pulmonary DiseaseBelgium
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Ottawa Heart Institute Research CorporationHeart and Stroke Foundation of OntarioCompletedMyocardial Infarction | Coronary ArteriosclerosisCanada
-
US Department of Veterans AffairsCompletedAging | Mobility LimitationsUnited States
-
University of Vic - Central University of CataloniaThe Social Services AdministrationCompletedPromotion of Healthy Eating Habits and Physical Activity Among Children and Their Families. (ALIAFF)Physical Activity | Children | Food Habits | FamiliesSpain
-
University of AlbertaRecruitingProstate Cancer | Metabolic Disease | IncontinenceCanada
-
Universidad Santo TomasEmory University; Universidad Pública de Navarra; Universidad de Granada; University... and other collaboratorsCompletedObesity | Lipid Metabolism Disorders | Mental Health Wellness 1 | Body Composition, Beneficial | Metabolic Syndrome X
-
University of MiamiAcademy of Spinal Cord Injury Professionals, Inc.Active, not recruiting
-
University Hospital Center of MartiniqueClinique Antilles-GuyaneUnknownDiabetes Mellitus, Type 2France
-
Saglik Bilimleri UniversitesiRecruitingAutism Spectrum Disorder | Telerehabilitation | Nutrition | Physiotherapy and RehabilitationTurkey